Publication at Second Faculty of Medicine |
2021
Abstract
Pediatric acute myeloid leukemia (AML) is a rare, heterogeneous disease, characterized by recurrent cytogenetic and molecular aberrations. Genetic aberrations are the most important prognostic factor, besides early response to treatment.
Here, we present the results of a collaborative study between the Children's Oncology Group (COG) and European AML study groups, aimed to define the biological and clinical characteristics of AML patients carrying NUP98-KDM5A outside acute megakaryoblastic leukemia.